Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet. 1984;1:1311–5.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.
Graham DY, Klein PD, Evans Jr DJ, et al. Campylobacter pylori detected noninvasively by the 13C-urea breath test. Lancet. 1987;1:1174–7.
Marshall BJ, Surveyor I. Carbon-14 urea breath test for the diagnosis of Campylobacter pylori associated gastritis. J Nucl Med. 1988;29:11–6.
Miki K. Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels—“ABC method”. Proc Jpn Acad Ser B Phys Biol Sci. 2011;87:405–14.
Kurilovich S, Belkovets A, Reshetnikov O, et al. Stomach-specific Biomarkers (GastroPanel) Can Predict the Development of Gastric Cancer in a Caucasian Population: A Longitudinal Nested Case-Control Study in Siberia. Anticancer Res. 2016;36:247–53.
Sai S, Ichikawa D, Tomita H, et al. Quantification of plasma cell-free DNA in patients with gastric cancer. Anticancer Res. 2007;27:2747–51.
Park JL, Kim HJ, Choi BY, et al. Quantitative analysis of cell-free DNA in the plasma of gastric cancer patients. Oncol Lett. 2012;3:921–6.
Kim K, Shin DG, Park MK, et al. Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection. Ann Surg Treat Res. 2014;86:136–42.
Ichikawa D, Koike H, Ikoma H, et al. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res. 2004;24:2477–81.
Ikoma H, Ichikawa D, Daito I, et al. Clinical application of methylation specific-polymerase chain reaction in serum of patients with gastric cancer. Hepatogastroenterology. 2007;54:946–50.
Lee TL, Leung WK, Chan MW, et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin Cancer Res. 2002;8:1761–6.
Kanyama Y, Hibi K, Nakayama H, et al. Detection of p16 promoter hypermethylation in serum of gastric cancer patients. Cancer Sci. 2003;94:418–20.
Koike H, Ichikawa D, Ikoma H, et al. Comparison of methylation-specific polymerase chain reaction (MSP) with reverse transcriptase-polymerase chain reaction (RT-PCR) in peripheral blood of gastric cancer patients. J Surg Oncol. 2004;87:182–6.
Koike H, Ichikawa D, Ikoma H, et al. Comparison of serum aberrant methylation and conventional tumor markers in gastric cancer patients. Hepatogastroenterology. 2005;52:1293–6.
Raja UM, Gopal G, Rajkumar T. Intragenic DNA methylation concomitant with repression of ATP4B and ATP4A gene expression in gastric cancer is a potential serum biomarker. Asian Pac J Cancer Prev. 2012;13:5563–8.
Ikoma H, Ichikawa D, Koike H, et al. Correlation between serum DNA methylation and prognosis in gastric cancer patients. Anticancer Res. 2006;26:2313–6.
Ling ZQ, Lv P, Lu XX, et al. Circulating Methylated DNA Indicates Poor Prognosis for Gastric Cancer. PLoS One. 2013;8:e67195.
Sakakura C, Hamada T, Miyagawa K, et al. Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer Res. 2009;29:2619–25.
Sapari NS, Loh M, Vaithilingam A, Soong R. Clinical potential of DNA methylation in gastric cancer: a meta-analysis. PLoS One. 2012;7:e36275.
Schurr PG, Oikonomou D, Kaifi JT, et al. Clinical value of loss of heterozygosity in serum microsatellite DNA of patients with gastrointestinal stromal tumors. J Clin Gastroenterol. 2009;43:27–35.
Rawnaq T, Schwarzenbach H, Schurr PG, et al. Monitoring of loss of heterozygosity in serum microsatellite DNA among patients with gastrointestinal stromal tumors indicates tumor recurrence. J Surg Res. 2011;169:31–5.
Maeta M, Saito H, Oka S, et al. Mutated p53 in tumors, mutant p53 and p53-specific antibodies in the circulation in patients with gastric cancer. J Exp Clin Cancer Res. 2000;19:489–95.
Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer. 2010;102:1174–9.
Zhou H, Guo JM, Lou YR, et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med (Berl). 2010;88:709–17.
Zheng Y, Cui L, Sun W, et al. MicroRNA-21 is a new marker of circulating tumor cells in gastric cancer patients. Cancer Biomark. 2011;10:71–7.
Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer. 2011;47:784–91.
Liu H, Zhu L, Liu B, et al. Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett. 2012;316:196–203.
Konishi H, Ichikawa D, Komatsu S, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. Br J Cancer. 2012;106:740–7.
Gorur A, Balci Fidanci S, Dogruer Unal N, et al. Determination of plasma microRNA for early detection of gastric cancer. Mol Biol Rep. 2013;40:2091–6.
Song JH, Meltzer SJ. MicroRNAs in pathogenesis, diagnosis, and treatment of gastroesophageal cancers. Gastroenterology. 2012;143:35–47. e32
Li C, Li JF, Cai Q, et al. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol. 2013;108:89–92.
Zhang WH, Gui JH, Wang CZ, et al. The identification of miR-375 as a potential biomarker in distal gastric adenocarcinoma. Oncol Res. 2012;20:139–47.
Zhu X, Lv M, Wang H, Guan W. Identification of circulating microRNAs as novel potential biomarkers for gastric cancer detection: a systematic review and meta-analysis. Dig Dis Sci. 2014;59:911–9.
Zhou X, Ji G, Chen H, et al. Clinical role of circulating miR-223 as a novel biomarker in early diagnosis of cancer patients. Int J Clin Exp Med. 2015;8:16890–8.
Tsai KW, Liao YL, Wu CW, et al. Aberrant expression of miR-196a in gastric cancers and correlation with recurrence. Genes Chromosomes Cancer. 2012;51:394–401.
Ma GJ, Gu RM, Zhu M, et al. Plasma post-operative miR-21 expression in the prognosis of gastric cancers. Asian Pac J Cancer Prev. 2013;14:7551–4.
Kim SY, Jeon TY, Choi CI, et al. Validation of circulating miRNA biomarkers for predicting lymph node metastasis in gastric cancer. J Mol Diagn. 2013;15:661–9.
Komatsu S, Ichikawa D, Tsujiura M, et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. Anticancer Res. 2013;33:271–6.
Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. J Transl Med. 2012;10:186.
Wang M, Gu H, Wang S, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. Mol Med Rep. 2012;5:1514–20.
Li BS, Zhao YL, Guo G, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. PLoS One. 2012;7:e41629.
Zhu C, Ren C, Han J, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. Br J Cancer. 2014;110:2291–9.
Li C, Li JF, Cai Q, et al. miRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. Ann Surg Oncol. 2013;20(Suppl 3):S397–405.
Rotkrua P, Shimada S, Mogushi K, et al. Circulating microRNAs as biomarkers for early detection of diffuse-type gastric cancer using a mouse model. Br J Cancer. 2013;108:932–40.
Pang Q, Ge J, Shao Y, et al. Increased expression of long intergenic non-coding RNA LINC00152 in gastric cancer and its clinical significance. Tumour Biol. 2014;35:5441–7.
Arita T, Ichikawa D, Konishi H, et al. Circulating long non-coding RNAs in plasma of patients with gastric cancer. Anticancer Res. 2013;33:3185–93.
Liu Z, Shao Y, Tan L, et al. Clinical significance of the low expression of FER1L4 in gastric cancer patients. Tumour Biol. 2014;35:9613–7.
Dong L, Qi P, Xu MD, et al. Circulating CUDR, LSINCT-5 and PTENP1 long noncoding RNAs in sera distinguish patients with gastric cancer from healthy controls. Int J Cancer. 2015;137:1128–35.
Shimada H, Noie T, Ohashi M, et al. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer. 2014;17:26–33.
Deng K, Yang L, Hu B, et al. The prognostic significance of pretreatment serum CEA levels in gastric cancer: a meta-analysis including 14651 patients. PLoS One. 2015;10:e0124151.
Song YX, Huang XZ, Gao P, et al. Clinicopathologic and Prognostic Value of Serum Carbohydrate Antigen 19-9 in Gastric Cancer: A Meta-Analysis. Dis Markers. 2015;2015:549843.
Zayakin P, Ancans G, Silina K, et al. Tumor-associated autoantibody signature for the early detection of gastric cancer. Int J Cancer. 2013;132:137–47.
Zhang JY, Casiano CA, Peng XX, et al. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev. 2003;12:136–43.
Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res. 2003;9:5120–6.
Zhou SL, Ku JW, Fan ZM, et al. Detection of autoantibodies to a panel of tumor-associated antigens for the diagnosis values of gastric cardia adenocarcinoma. Dis Esophagus. 2015;28:371–9.
Xu QW, Zhao W, Wang Y, et al. An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. Cancer Res. 2012;72:6351–61.
Looi K, Megliorino R, Shi FD, et al. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep. 2006;16:1105–10.
Zhang JY, Chan EK, Peng XX, et al. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol. 2001;100:149–56.
Werner S, Chen H, Tao S, Brenner H. Systematic review: serum autoantibodies in the early detection of gastric cancer. Int J Cancer. 2015;136:2243–52.
Ebert MP, Meuer J, Wiemer JC, et al. Identification of gastric cancer patients by serum protein profiling. J Proteome Res. 2004;3:1261–6.
Liang Y, Fang M, Li J, et al. Serum proteomic patterns for gastric lesions as revealed by SELDI mass spectrometry. Exp Mol Pathol. 2006;81:176–80.
Lu HB, Zhao C, Ma YY. The early gastric clinical significance of serum protein fingerprint diagnostic. Progress Med Biomed. 2006;11:120–6.
Poon TC, Sung JJ, Chow SM, et al. Diagnosis of gastric cancer by serum proteomic fingerprinting. Gastroenterology. 2006;130:1858–64.
Lim JY, Cho JY, Paik YH, et al. Diagnostic application of serum proteomic patterns in gastric cancer patients by ProteinChip surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Int J Biol Markers. 2007;22:281–6.
Su Y, Shen J, Qian H, et al. Diagnosis of gastric cancer using decision tree classification of mass spectral data. Cancer Sci. 2007;98:37–43.
Wang YS, Shen J, Yu JK, et al. [Protein profiles of serum in gastric cancer at a high-risk area by SELDI-TOF mass spectrometry]. Zhonghua Yu Fang Yi Xue Za Zhi. 2008;42:677–80.
Liu C, Xu L, Han HB. Preliminary study of serum protein fingerprint screening gastric cancer serum markers. Bases Clin Med. 2009;16:237–40.
Xue WC, Feng K, Meng DY. Serum protein fingerprint for the early diagnosis of gastric cancer. J Pract Diagn Ther. 2009;18:153–6.
Lu HB, Zhou JH, Ma YY, et al. Five serum proteins identified using SELDI-TOF-MS as potential biomarkers of gastric cancer. Jpn J Clin Oncol. 2010;40:336–42.
Liu W, Gao X, Cai Q. Identification of novel serum biomarkers for gastric cancer by magnetic bead. Front Biosci (Elite Ed). 2010;2:961–71.
Wang WJ, Liu C, Liu P. SELDI-TOF-MS technology screening gastric cancer serum markers. Environ Occup Med. 2007;24:143–6.
Ebert MP, Niemeyer D, Deininger SO, et al. Identification and confirmation of increased fibrinopeptide a serum protein levels in gastric cancer sera by magnet bead assisted MALDI-TOF mass spectrometry. J Proteome Res. 2006;5:2152–8.
Kobayashi Y, Niwa Y, Tajika M, et al. Serum tumor antigen REG4 as a useful diagnostic biomarker in gastric cancer. Hepatogastroenterology. 2010;57:1631–4.
Zheng ZG, Xu SH, Xu Q, et al. [Use of serum protein profiling for early diagnosis of gastric cancer]. Zhonghua Wei Chang Wai Ke Za Zhi. 2010;13:770–3.
Umemura H, Togawa A, Sogawa K, et al. Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis. J Gastroenterol. 2011;46:577–85.
Tseng CW, Yang JC, Chen CN, et al. Identification of 14-3-3beta in human gastric cancer cells and its potency as a diagnostic and prognostic biomarker. Proteomics. 2011;11:2423–39.
Cohen M, Yossef R, Erez T, et al. Serum apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. PLoS One. 2011;6:e14540.
Ahn HS, Shin YS, Park PJ, et al. Serum biomarker panels for the diagnosis of gastric adenocarcinoma. Br J Cancer. 2012;106:733–9.
Liu W, Liu B, Cai Q, et al. Proteomic identification of serum biomarkers for gastric cancer using multi-dimensional liquid chromatography and 2D differential gel electrophoresis. Clin Chim Acta. 2012;413:1098–106.
Yang J, Xiong X, Wang X, et al. Identification of peptide regions of SERPINA1 and ENOSF1 and their protein expression as potential serum biomarkers for gastric cancer. Tumour Biol. 2015;36:5109–18.
Loei H, Tan HT, Lim TK, et al. Mining the gastric cancer secretome: identification of GRN as a potential diagnostic marker for early gastric cancer. J Proteome Res. 2012;11:1759–72.
Gomceli I, Bostanci EB, Ozer I, et al. A novel screening biomarker in gastric cancer: serum Dickkopf-1. Hepatogastroenterology. 2012;59:1661–4.
Fan NJ, Li K, Liu QY, et al. Identification of tubulin beta chain, thymosin beta-4-like protein 3, and cytochrome b-c(1) complex subunit 1 as serological diagnostic biomarkers of gastric cancer. Clin Biochem. 2013;46:1578–84.
Gomes C, Almeida A, Ferreira JA, et al. Glycoproteomic analysis of serum from patients with gastric precancerous lesions. J Proteome Res. 2013;12:1454–66.
Ren J, Chen Z, Juan SJ, et al. Detection of circulating gastric carcinoma-associated antigen MG7-Ag in human sera using an established single determinant immuno-polymerase chain reaction technique. Cancer. 2000;88:280–5.
Fang X, Tie J, Xie Y, et al. Detection of gastric carcinoma-associated antigen MG7-Ag in human sera using surface plasmon resonance sensor. Cancer Epidemiol. 2010;34:648–51.
Zeng Z, Fu S, Hu P, et al. The diagnostic value of monoclonal gastric cancer 7 antigen: a systematic review with meta-analysis. Clin Exp Med. 2014;14:337–43.
Helgason HH, Engwegen JY, Zapatka M, et al. Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncol Lett. 2010;1:327–33.
Chan DC, Chen CJ, Chu HC, et al. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann Surg Oncol. 2007;14:84–93.
Qiu FM, Yu JK, Chen YD, et al. Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res. 2009;28:126.
Tao HQ, He XJ, Ma YY, et al. Evaluation of REG4 for early diagnosis and prognosis of gastric cancer. Hum Pathol. 2011;42:1401–9.
Yasuda H, Toiyama Y, Ohi M, et al. Serum soluble vascular adhesion protein-1 is a valuable prognostic marker in gastric cancer. J Surg Oncol. 2011;103:695–9.
Yu L, Aa J, Xu J, et al. Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol. 2011;26:1290–7.
Song H, Peng JS, Dong-Sheng Y, et al. Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res. 2012;45:78–85.
Ikeda A, Nishiumi S, Shinohara M, et al. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr. 2012;26:548–58.
Miyagi Y, Higashiyama M, Gochi A, et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One. 2011;6:e24143.
Tang L, Zhao S, Liu W, et al. Diagnostic accuracy of circulating tumor cells detection in gastric cancer: systematic review and meta-analysis. BMC Cancer. 2013;13:314.
Uenosono Y, Arigami T, Kozono T, et al. Clinical significance of circulating tumor cells in peripheral blood from patients with gastric cancer. Cancer. 2013;119:3984–91.
Ito H, Inoue H, Sando N, et al. Prognostic impact of detecting viable circulating tumour cells in gastric cancer patients using a telomerase-specific viral agent: a prospective study. BMC Cancer. 2012;12:346.
Matsusaka S, Chin K, Ogura M, et al. Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer. Cancer Sci. 2010;101:1067–71.
Hiraiwa K, Takeuchi H, Hasegawa H, et al. Clinical significance of circulating tumor cells in blood from patients with gastrointestinal cancers. Ann Surg Oncol. 2008;15:3092–100.
Cao W, Yang W, Li H, et al. Using detection of survivin-expressing circulating tumor cells in peripheral blood to predict tumor recurrence following curative resection of gastric cancer. J Surg Oncol. 2011;103:110–5.
Bertazza L, Mocellin S, Marchet A, et al. Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival. J Transl Med. 2009;7:111.
Yie SM, Lou B, Ye SR, et al. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol. 2008;15:3073–82.
Yeh KH, Chen YC, Yeh SH, et al. Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 (K19)--possible clinical significance in advanced gastric cancer. Anticancer Res. 1998;18:1283–6.
Marrelli D, Pinto E, De Stefano A, et al. Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer. Am J Surg. 2001;181:16–9.
Illert B, Fein M, Otto C, et al. Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosis. Scand J Gastroenterol. 2005;40:843–9.
Kolodziejczyk P, Pituch-Noworolska A, Drabik G, et al. The effects of preoperative chemotherapy on isolated tumour cells in the blood and bone marrow of gastric cancer patients. Br J Cancer. 2007;97:589–92.
Koga T, Tokunaga E, Sumiyoshi Y, et al. Detection of circulating gastric cancer cells in peripheral blood using real time quantitative RT-PCR. Hepatogastroenterology. 2008;55:1131–5.
Wu CH, Lin SR, Hsieh JS, et al. Molecular detection of disseminated tumor cells in the peripheral blood of patients with gastric cancer: evaluation of their prognostic significance. Dis Markers. 2006;22:103–9.
Ikeguchi M, Kaibara N. Detection of circulating cancer cells after a gastrectomy for gastric cancer. Surg Today. 2005;35:436–41.
Mimori K, Fukagawa T, Kosaka Y, et al. A large-scale study of MT1-MMP as a marker for isolated tumor cells in peripheral blood and bone marrow in gastric cancer cases. Ann Surg Oncol. 2008;15:2934–42.
Arigami T, Uenosono Y, Hirata M, et al. B7-H3 expression in gastric cancer: a novel molecular blood marker for detecting circulating tumor cells. Cancer Sci. 2011;102:1019–24.
Baran J, Baj-Krzyworzeka M, Weglarczyk K, et al. Circulating tumour-derived microvesicles in plasma of gastric cancer patients. Cancer Immunol Immunother. 2010;59:841–50.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Dakubo, G.D. (2017). Gastric Cancer Biomarkers in Circulation. In: Cancer Biomarkers in Body Fluids. Springer, Cham. https://doi.org/10.1007/978-3-319-48360-3_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-48360-3_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-48359-7
Online ISBN: 978-3-319-48360-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)